November 18, 2026
Health news, explained with evidence
LIVE

Glycolytic Inhibitor Shows Potential in Protecting Against Type 1 Diabetes in Animal Models

🧠 AI Analysis 2 min read 👁 4

Researchers at Kobe University found that oral administration of the glycolytic inhibitor 2-deoxy-D-glucose suppressed autoimmune diabetes progression in mouse models by altering immune cell activity.

🧠AI Analysis

Key points

  • Oral 2DG treatment suppressed type 1 diabetes progression in mouse models.
  • The compound altered immune cell populations, increasing regulatory T cells.
  • Findings remain limited to preclinical animal studies and require clinical validation.

A study published in Nature Health Sciences by researchers from Kobe University investigated the effects of the glycolytic inhibitor 2-deoxy-D-glucose (2DG) on type 1 diabetes development. Type 1 diabetes is an autoimmune condition driven by T cells destroying pancreatic beta cells. To explore potential interventions, the research team administered oral 2DG to two distinct mouse models of type 1 diabetes.

Findings in Animal Models

In the first evaluation using a cyclophosphamide-induced model in male non-obese diabetic mice, oral 2DG treatment successfully suppressed autoimmune insulitis and the onset of diabetes. The treatment led to a notable drop in CD44hiCD4+ T cells and CD11b+ macrophages, alongside an increase in regulatory T cells (Tregs) and protective PD-L1+ macrophages. A second evaluation using a spontaneous model in female mice yielded similar outcomes, reinforcing that 2DG may limit autoimmune progression and reduce insulitis.

What to know: This study was conducted exclusively in animal models, meaning these preliminary results cannot yet be directly extrapolated to human patients. The findings suggest that metabolic regulation—specifically via reduced glucose uptake in immune cells like B cells—may influence autoimmune responses, but further clinical research is required. Readers should consult a qualified healthcare professional for guidance regarding any personal medical decisions or diabetes management.

Source Nature Health Sciences — nature.com/articles/s41598-026-70088-2 ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.